Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2025.110718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Xueying Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Oxcarbazepine, Lacosamide, Epilepsies, Partial, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Key Research and Development Projects of Shaanxi Province.
Abstract (Originalsprache)
OBJECTIVE: To investigate the clinical efficacy and safety of the combination of lacosamide (LCM) and oxcarbazepine (OXC) in children with focal epilepsy, either as a dual therapy or in combination with other anti-seizure medications. METHODS: We collected clinical data retrospectively from pediatric epilepsy patients treated with both LCM and OXC for at least 6 months at the Department of Pediatrics, Second Affiliated Hospital of Xi'an Jiaotong University, between January 2021 and July 2023. Efficacy and adverse events were investigated. RESULTS: Collectively, 69 pediatric patients were included, with ages ranging from 1 to 18 years. The age at onset of epilepsy varied from 15 days to 14.8 years. Disease duration ranged from 1 month to 14 years. All pediatric patients exhibited focal seizures, with the maximum number of concurrent combined medications being six. The maintenance dose of LCM for all pediatric patients was between 3.8 and 10 mg/kg, while that of OXC was between 15 and 40 mg/kg. Over half of the patients showed a greater than 50 % reduction in seizure frequency during long-term follow-up. The most frequently reported adverse reactions included hyponatremia, headache, dizziness, somnolence, and nausea; no patients experienced rash as an adverse reaction. CONCLUSION: The combination of LCM and OXC has shown promising efficacy and tolerability in pediatric patients with focal epilepsy. This therapeutic combination is a worthwhile option to consider for patients with focal epilepsy, especially those with underlying structural abnormalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- College of Medicine and Forensics, Xi'an Jiaotong University Health Science Center, Xi'an, China. Electronic address: psydyh@mail.xjtu.edu.cn.
Förderung
- Key Research and Development Projects of Shaanxi Province
Zitieren
APA
Wang, X., Yang, L., Huang, S., Li, D., Liu, Y., Guo, Y., Sun, N., Ye, G., & Dang, Y. (2025). Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110718
Vancouver
Wang X, Yang L, Huang S, Li D, Liu Y, Guo Y, et al. Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110718
BibTeX
@article{Wang2025,
author = {Wang, Xueying and Yang, Lin and Huang, Shaoping and Li, Dan and Liu, Yu and Guo, Yingying and Sun, Na and Ye, Gaobo and Dang, Yonghui},
title = {Efficacy and safety of long-term combination therapy with lacosamide and oxcarbazepine for pediatric patients with focal epilepsy: real-world clinical experience},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2025.110718}
}
EUVIMED